Enveric Biosciences, Inc. (ENVB): Lienzo del Modelo de Negocio [Actualizado en Ene-2025]

En el paisaje en rápida evolución de la terapéutica de salud mental, Enveric Biosciences, Inc. (ENVB) emerge como una fuerza pionera, aprovechando el potencial transformador de los compuestos derivados de psicodélicos para revolucionar los paradigmas de tratamiento. Al crear meticulosamente un modelo de negocio integral que une la investigación científica de vanguardia, las asociaciones estratégicas y el desarrollo innovador de medicamentos, la compañía está a punto de desbloquear soluciones innovadoras para las condiciones de salud mental resistentes al tratamiento. Su enfoque único entrea en tecnologías avanzadas de detección molecular, investigación patentada y una visión centrada en el paciente que podría remodelar cómo conceptualizamos y abordamos desafíos neurológicos complejos.

Enveric Biosciences, Inc. (ENVB) - Modelo de negocios: asociaciones clave

Colaboración estratégica con instituciones de investigación académica

A partir de 2024, Enveric Biosciences ha establecido asociaciones de investigación con las siguientes instituciones académicas:

Institución	Enfoque de investigación	Año de asociación
Universidad de Johns Hopkins	Terapias de salud mental basadas en psicodélica	2022
Universidad de Miami	Investigación del trastorno neurológico	2023

Asociación con Laboratorios de Desarrollo Farmacéutico

Enveric Biosciences ha colaborado con Laboratorios de Desarrollo Farmacéutico para avanzar en su tubería de descubrimiento de fármacos:

• Asociación de desarrollo preclínico con Battelle Memorial Institute
• Colaboración de pruebas analíticas con Medpace Laboratories

Acuerdos de licencia para compuestos terapéuticos basados ​​en psicodélico

Los acuerdos de licencia actuales incluyen:

Compuesto	Licenciante	Términos de licencia
EB-841	Universidad de California	Derechos mundiales exclusivos
EB-505	Instituto de Neurociencia de Stanford	Derechos exclusivos de América del Norte

Redes de colaboración de ensayos clínicos potenciales

Enveric Biosciences ha establecido conexiones con redes de ensayos clínicos:

• Icon PLC Organización de investigación clínica
• Red de gestión de ensayos clínicos de IQVIA
• Plataforma de ensayo clínico digital medible

Inversión total de asociación de investigación: $ 3.2 millones en 2023

Presupuesto de investigación colaborativa proyectada para 2024: $ 4.5 millones

Enveric Biosciences, Inc. (EnvB) - Modelo de negocio: actividades clave

Investigación y desarrollo de tratamientos terapéuticos derivados de psicodélicos

A partir de 2024, Enveric Biosciences se centra en el desarrollo de tratamientos terapéuticos derivados de psicodélicos con parámetros de investigación específicos:

Área de enfoque de investigación	Inversión actual	Etapa de investigación
Desarrollo compuesto psicodélico	$ 3.2 millones	Preclínico
Tratamientos de trastorno neurológico	$ 2.7 millones	Descubrimiento temprano
Compuestos terapéuticos de salud mental	$ 4.1 millones	Cribado molecular

Gestión de ensayos preclínicos y clínicos

Las actividades de gestión del ensayo clínico incluyen:

• Desarrollo de protocolo para tratamientos psicodélicos
• Estrategias de reclutamiento de pacientes
• Monitoreo de cumplimiento regulatorio
• Recopilación y análisis de datos

Tipo de prueba	Número de pruebas activas	Recuento total de participantes
Pruebas preclínicas	3	N / A
Pruebas de fase I	2	45 participantes

Descubrimiento de fármacos y detección de compuestos moleculares

Parámetros de detección molecular:

• Compuestos de detección anualmente: 500-750 estructuras moleculares únicas
• Inversión de modelado computacional: $ 1.5 millones
• Capacidad de detección de alto rendimiento: 10,000 compuestos por mes

Desarrollo y protección de la propiedad intelectual

Categoría de IP	Patentes totales	Gasto de protección de patentes
Compuestos moleculares	12	$650,000
Metodologías de tratamiento	8	$420,000

Enveric Biosciences, Inc. (ENVB) - Modelo de negocio: recursos clave

Investigación especializada y experiencia científica en medicina psicodélica

A partir del cuarto trimestre de 2023, Enveric Biosciences mantiene un equipo de investigación de 12 profesionales científicos con experiencia especializada en medicina psicodélica.

Composición del equipo de investigación	Número de profesionales
Investigadores de doctorado	7
Especialistas en investigación clínica	5

Tecnologías avanzadas de detección molecular y desarrollo farmacéutico

Enveric Biosciences utiliza plataformas de detección molecular patentadas con las siguientes especificaciones técnicas:

• Capacidades de detección de alto rendimiento: 100,000 compuestos por semana
• Infraestructura avanzada de modelado computacional
• Algoritmos de descubrimiento de fármacos habilitados para el aprendizaje automático

Bibliotecas compuestas propuestas y conjuntos de datos de investigación

Detalles de la biblioteca compuesta	Métricas cuantitativas
Totales compuestos únicos	385 estructuras moleculares relacionadas con psicodélica
Conjuntos de datos de investigación	67 Archivos integrales de investigación preclínica y clínica

Cartera de propiedades intelectuales

A diciembre de 2023, Enveric Biosciences posee:

• 6 Patentes otorgadas en terapéutica de salud mental
• 12 solicitudes de patentes pendientes
• Propiedad intelectual centrada en la psilocibina y los compuestos derivados

Categoría de IP	Número de activos
Patentes concedidas	6
Aplicaciones de patentes pendientes	12

Enveric Biosciences, Inc. (EnvB) - Modelo de negocio: propuestas de valor

Soluciones terapéuticas innovadoras para los trastornos de la salud mental

Enveric Biosciences se centra en el desarrollo de compuestos terapéuticos basados ​​en psicodélicos dirigidos a afecciones de salud mental específicas. A partir del cuarto trimestre de 2023, la compañía tiene:

Área terapéutica	Candidato a la droga	Etapa de desarrollo
Depresión	EB-101	Preclínico
Trastorno	EB-102	De investigación
Trastornos de ansiedad	EB-103	Investigación temprana

Desarrollo de drogas novedoso utilizando compuestos psicodélicos

La cartera de investigación de la compañía incluye:

• Modificaciones moleculares patentadas de compuestos psicodélicos
• Desarrollo analógico sintético dirigido a vías neurológicas
• Cartera de propiedades intelectuales con 7 solicitudes de patentes

Posibles tratamientos innovadores para afecciones resistentes al tratamiento

Enveric Biosciences se dirige a condiciones de salud mental resistentes al tratamiento con necesidades clínicas no satisfechas. Las áreas de enfoque de investigación clave incluyen:

Condición	Potencial de mercado	Porcentaje de necesidad insatisfecha
Depresión resistente al tratamiento	$ 3.5 mil millones	35%
Trastorno	$ 2.8 mil millones	45%
Ansiedad crónica	$ 2.2 mil millones	40%

Terapias dirigidas con efectos secundarios potencialmente reducidos

Análisis comparativo de los perfiles potenciales de efectos secundarios:

• Efectos secundarios neurológicos reducidos en comparación con los antidepresivos tradicionales
• Potencial para un inicio más rápido de efectos terapéuticos
• Interferencia metabólica más baja con los medicamentos existentes

Gastos de investigación y desarrollo en 2023: $ 4.2 millones dedicados a la optimización compuesta y las estrategias de investigación clínica.

Enveric Biosciences, Inc. (ENVB) - Modelo de negocios: relaciones con los clientes

Compromiso directo con la comunidad de investigación médica

Enveric Biosciences mantiene asociaciones de investigación directa con las siguientes instituciones académicas:

Institución	Enfoque de investigación	Estado de colaboración
Universidad de Johns Hopkins	Investigación de medicina psicodélica	Asociación activa
Universidad de California	Estudios de trastorno neurológico	Colaboración en curso

Enfoque colaborativo con profesionales clínicos

Métricas de participación clínica para 2024:

• Red total de profesionales clínicos: 87 especialistas
• Áreas especializadas cubiertas: psiquiatría, neurología, oncología
• Consultas de protocolo de investigación: 42 protocolos activos

Desarrollo terapéutico centrado en el paciente

Las estrategias de participación del paciente incluyen:

Canal de compromiso	Número de participantes	Programas de apoyo al paciente
Reclutamiento de ensayos clínicos	213 pacientes	Programa de asistencia al paciente
Mecanismos de retroalimentación del paciente	167 encuestados activos	Plataforma de soporte digital

Conferencia científica y participación en eventos de la industria

2024 Detalles de participación de la conferencia:

• CONFERENCIAS TOTALES CONTENIDAS: 9
• Sesiones de presentación: 5
• Presentaciones de carteles: 4
• Eventos clave:
  • Reunión anual de la Asociación Americana de Asociación Psiquiátrica
  • Conferencia internacional de neuropsychofarmacología

Enveric Biosciences, Inc. (ENVB) - Modelo de negocio: canales

Publicación científica directa y presentación de investigación

Tipo de publicación	Frecuencia	Plataformas
Revistas revisadas por pares	2-3 publicaciones por año	Nature Biotechnology, Journal of Psychopharmacology
Presentaciones de conferencias de investigación	4-5 presentaciones anualmente	Conferencias internacionales de neuropsicofarmacología

Conferencias de la industria farmacéutica

Participación de la conferencia clave:

• Reunión anual de la Asociación Americana de Asociación Psiquiátrica
• Conferencia de la Sociedad de Neurociencia
• Conferencia internacional de cannabis y psicodélicos

Comunicaciones de relaciones con los inversores

Canal de comunicación	Frecuencia	Alcanzar
Llamadas de ganancias trimestrales	4 veces al año	Inversores institucionales, accionistas minoristas
Presentaciones de inversores	6-8 por año	Conferencias financieras, foros de inversores

Interacciones de la red de investigación académica y médica

Redes de colaboración:

• Centro de investigación psicodélica de la Universidad Johns Hopkins
• División de Psicofarmacología de la Salud NYU Langone
• Instituto de Neurociencia de la Universidad de California en San Francisco

Enveric Biosciences, Inc. (ENVB) - Modelo de negocio: segmentos de clientes

Profesionales de tratamiento de salud mental

Tamaño del segmento objetivo: aproximadamente 1.1 millones de profesionales de la salud mental con licencia en los Estados Unidos a partir de 2023.

Categoría profesional	Número de practicantes
Psiquiatras	45,981
Psicólogos	106,750
Trabajadores sociales clínicos con licencia	729,000

Instituciones de investigación farmacéutica

Las instituciones de investigación totales se centraron en el desarrollo de fármacos de salud mental: 287 a partir de 2024.

• Institutos Nacionales de Salud (NIH) Presupuesto de investigación de salud mental: $ 2.3 mil millones en 2023
• Instituciones de investigación privadas: 112
• Centros de investigación académica: 175

Pacientes con afecciones de salud mental resistentes al tratamiento

Población potencial total de pacientes: 16.1 millones de adultos con afecciones resistentes al tratamiento en los Estados Unidos.

Condición de salud mental	Pacientes resistentes al tratamiento
Trastorno depresivo mayor	4.5 millones
Depresión resistente al tratamiento	2.8 millones
Trastornos de ansiedad	6.8 millones
Trastorno	2 millones

Inversores de biotecnología y atención médica

Inversión total en sector de biotecnología de salud mental: $ 7.6 mil millones en 2023.

• Inversiones de capital de riesgo: $ 3.2 mil millones
• Inversiones de capital privado: $ 1.9 mil millones
• Asignación de inversores institucionales: $ 2.5 mil millones

Capitalización de mercado de Enveric Biosciences a partir de enero de 2024: $ 12.4 millones

Enveric Biosciences, Inc. (EnvB) - Modelo de negocio: Estructura de costos

Extensos gastos de investigación y desarrollo

Según los informes financieros de la compañía para el año fiscal 2023, Enveric Biosciences asignó los siguientes gastos de I + D:

Categoría de gastos	Monto ($)
Gastos totales de I + D	3,742,000
Investigación preclínica	1,285,000
Descubrimiento de drogas	1,457,000

Gestión de ensayos clínicos y costos operativos

Los gastos de ensayos clínicos de la compañía para 2023 se estructuraron de la siguiente manera:

• Ensayos clínicos de fase I: $ 2,100,000
• Ensayos clínicos de fase II: $ 4,350,000
• Gestión de operaciones clínicas: $ 1,250,000
• Cumplimiento regulatorio: $ 675,000

Registro y mantenimiento de la propiedad intelectual

Costos de propiedad intelectual para Enveric Biosciences en 2023:

Categoría de gastos de IP	Monto ($)
Presentación de patentes	425,000
Mantenimiento de patentes	210,000
Consulta legal	185,000

Reclutamiento y retención de talento científico

Gastos relacionados con el personal para el personal científico en 2023:

• Salarios totales de personal científico: $ 5,600,000
• Costos de reclutamiento: $ 350,000
• Beneficios de los empleados: $ 1,120,000
• Capacitación y desarrollo: $ 275,000

Estructura de costos totales para 2023: $ 13,347,000

Enveric Biosciences, Inc. (ENVB) - Modelo de negocios: flujos de ingresos

Licencias potenciales de productos farmacéuticos futuros

A partir del cuarto trimestre de 2023, Enveric Biosciences no ha informado ningún ingreso activo de licencias de productos farmacéuticos.

Categoría de licencia potencial	Valor potencial estimado	Estado
Compuestos terapéuticos basados ​​en psicodélicos	No revelado	Etapa exploratoria
Candidatos a drogas de salud mental	No revelado	Desarrollo preclínico

Subvenciones de investigación y fondos académicos

Enveric Biosciences ha realizado fondos de investigación a través de varios canales académicos y científicos.

• Financiación total de la subvención de investigación para 2023: no revelado públicamente
• Presupuestos de colaboración de investigación: no revelado
• Inversión de asociación académica: detalles financieros mínimos informados

Acuerdos de investigación colaborativos

La compañía se ha dedicado a iniciativas de investigación colaborativa.

Socio de investigación	Área de enfoque	Contribución financiera
Instituciones de investigación académica	Terapéutica psicodélica	No especificado

Venta de productos terapéuticos potenciales

A partir de 2024, Enveric Biosciences no ha generado ingresos a partir de las ventas de productos terapéuticos debido a los procesos regulatorios en curso.

• Producto actual de productos: etapa preclínica
• Primer ingreso potencial proyectado: no establecido
• Línea de aprobación regulatoria: indeterminado

Nota: Los datos financieros reflejan información limitada disponible públicamente a partir del cuarto trimestre de 2023.

Enveric Biosciences, Inc. (ENVB) - Canvas Business Model: Value Propositions

You're looking at the core value Enveric Biosciences, Inc. (ENVB) is offering the market as they push EB-003 toward human trials. The value proposition centers on delivering next-generation neuroplastogenic small molecules for psychiatric disorders, specifically designed to avoid the major drawback of current psychedelic-inspired approaches: hallucinations.

Non-hallucinogenic neuroplastogen therapeutics for psychiatric disorders

The primary value is providing a therapeutic that promotes adaptive neural circuit remodeling, or neuroplasticity, without the adverse hallucinogenic outcomes associated with some other compounds. This characteristic is key to enabling outpatient administration for chronic conditions, which drastically reduces the treatment burden compared to models requiring specialized clinical settings.

The company is advancing EB-003 toward IND submission, with IND-enabling activities planned to continue through 2025, aiming for First-in-Human clinical trials in 2026. This progression is supported by a cash and cash equivalents balance of $3.8 million as of September 30, 2025, following net proceeds of $7.9 million raised in the first nine months of 2025 to fund this path.

EB-003's unique dual mechanism of action (5-HT2A/5-HT1B receptor engagement)

EB-003 is positioned as a first-in-class molecule because it selectively engages two key serotonin receptors. This dual targeting is what the company believes differentiates it in the crowded CNS space. The preclinical data supports this mechanism, showing EB-003 acts as a partial agonist of the 5-HT2A receptor and an agonist of the 5-HT1B receptor, with an EC50 of 110 nM for the latter.

The ability to achieve therapeutically relevant brain exposure is also a core value, demonstrated by a brain-to-plasma exposure ratio of approximately 1.5 in rodent models. This mechanism is intended to offer a superior profile compared to older treatments.

Here's a quick look at the data underpinning this value proposition:

Metric	Value/Finding	Context
5-HT1B Agonism (EC50)	110 nM	Preclinical data point for dual mechanism.
PTSD Preclinical Efficacy (p-value)	p < 0.05	Significantly decreased context-induced freezing behavior one-hour post-dose in a rodent model.
Brain-to-Plasma Ratio (Rodent)	Approx. 1.5	Indicates good brain penetration for a CNS therapeutic.
Q3 2025 Net Loss	$3.4 million	Financial context for R&D spend to achieve these milestones.

Potential for fast-acting, durable antidepressant and anxiolytic effects

The clinical promise tied to the dual mechanism is the potential for effects that are both rapid and long-lasting. In preclinical models for Post-Traumatic Stress Disorder (PTSD), a single oral dose of EB-003 resulted in a significant therapeutic effect, showing a p < 0.05 reduction in context-induced freezing behavior just one-hour post-dose. This rapid onset contrasts with the two to three weeks required for benefits from older drugs like SSRIs.

The value here is the potential to treat difficult-to-address mental health disorders with outpatient convenience and a reduced treatment frequency, which is a major step up from current standards where only 20% to 30% of PTSD patients experience full remission with existing SSRIs.

Out-licensable IP for non-competitive indications like joint pathologies

Enveric Biosciences is structuring its value capture to be dual-pronged: developing EB-003 internally while simultaneously monetizing other assets from its Psybrary™ platform through out-licensing. This strategy aims to capture value from non-competitive market strategies, which could include indications like joint pathologies, although specific data on joint pathology trials wasn't detailed in the latest reports.

The strength of this out-licensing value is grounded in a growing intellectual property estate. The company announced receipt of a Fourth Notice of Allowance for the EVM401 series of drug candidates and further enhanced its IP estate with a new U.S. Patent Issuance in October 2025. This focus on IP protection is a cornerstone of the company's overall value proposition.

• Advance EB-003 toward IND submission.
• Out-license other novel, patented Psybrary™ platform drug candidates.
• Fourth Notice of Allowance received for EVM401 series.
• New U.S. Patent Issuance in October 2025.

Finance: draft 13-week cash view by Friday.

Enveric Biosciences, Inc. (ENVB) - Canvas Business Model: Customer Relationships

You're looking at how Enveric Biosciences, Inc. manages its external relationships, which is critical for a clinical-stage biotech company relying on external validation and capital. These relationships span from formal contracts to high-stakes regulatory dialogue.

Contractual Relationships with Licensees

Enveric Biosciences, through its wholly-owned subsidiary Akos Biosciences, Inc., has established formal, exclusive, royalty-bearing global licenses with Restoration Biologics LLC for its cannabinoid-COX-2 conjugate compounds, covering both pharmaceutical and non-pharmaceutical applications for joint disease, such as osteoarthritis and rheumatoid arthritis.

These contractual relationships are structured around future performance milestones. The potential value embedded in these agreements is substantial, though contingent on successful development and commercialization by the licensee.

• Potential milestone payments for the pharmaceutical license: up to $61 million.
• Potential milestone payments for the non-pharmaceutical license: up to $21 million.
• Royalty rates on future sales are tiered, ranging from low single digit to low double digits.

Direct Engagement with Potential Big Pharma Partners for Strategic Deals

Direct engagement is focused on showcasing the value of its lead candidate, EB-003, and its broader Psybrary™ platform to established players in the neuropsychiatry space. This is a key avenue for potential out-licensing or strategic collaboration that can de-risk development.

The company actively seeks these interactions. For instance, CEO Joseph Tucker, Ph.D., conducted one-on-one meetings with potential partners during the BIO International Convention held in June 2025 in Boston, Massachusetts. Furthermore, management noted ongoing dialogue and growing interest from established pharmaceutical companies with a strategic focus in neuropsychiatry as of the second quarter of 2025.

High-Touch Relationship with the FDA via Pre-IND Meeting Requests

The relationship with the U.S. Food and Drug Administration (FDA) is high-touch, centered on advancing the lead candidate, EB-003, toward clinical trials. This involves direct, formal submissions and correspondence.

Enveric Biosciences recently received a written response from the FDA to its request for a Pre-Investigational New Drug (pre-IND) Type B meeting for EB-003. The FDA recommended that Enveric Biosciences proceed directly to submitting its Investigational New Drug (IND) application and protocol for review, which the company interprets as consistent with being sufficiently advanced in its development strategy. This streamlined the regulatory path, with the IND submission for EB-003 anticipated in early 2026.

• Preclinical data supporting the regulatory path included showing significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05) in a preclinical model of PTSD as of Q3 2025.
• The company successfully produced a 1-kilogram batch of EB-003 as a pharmaceutically compatible salt to support IND-enabling activities, including GLP toxicology studies.

Transactional Relationship with Investors via Equity Offerings

Investor relationships are primarily transactional, centered on securing the necessary capital to fund product development and working capital through equity and warrant exercises. This is the lifeblood for a company funding IND-enabling activities.

Here's a quick look at the financing activity near late 2025:

Financing Event/Metric	Amount/Date Reference
Gross Proceeds from February 2025 Offering	Approximately $5 million
Gross Proceeds from September 2025 Warrant Exercise	Approximately $2.2 million
Net Proceeds Raised (Nine Months Ended September 30, 2025)	$7.9 million
Cash and Cash Equivalents (As of September 30, 2025)	$3.8 million
Net Proceeds Raised (Six Months Ended June 30, 2025)	$4.9 million

The February 2025 offering involved shares, Series A warrants, and Series B warrants issued at a combined public offering price of $3.00 a share. Later, in September 2025, warrants were exercised at a reduced price of $0.915 per share, resulting in the $2.2 million gross proceeds. What this estimate hides is the dilution effect inherent in these financing tools, which is a constant consideration for existing shareholders.

Enveric Biosciences, Inc. (ENVB) - Canvas Business Model: Channels

You're looking at how Enveric Biosciences, Inc. (ENVB) gets its value proposition-novel neuroplastogenic therapeutics-out to the market and secures the necessary resources. For a preclinical biotech, the channels are less about direct sales and more about strategic partnerships and regulatory milestones that unlock future value or fund operations.

Direct Out-licensing agreements with pharmaceutical companies

Enveric Biosciences is actively using out-licensing as a primary channel to monetize its extensive Psybrary™ portfolio while keeping its lead asset, EB-003, in-house for development. This strategy brings in non-dilutive capital and validates the platform.

Here's a look at the potential value locked in these agreements:

License/Agreement Type	Potential Total Milestones	Royalty Rate Range (Future Sales)	Status/Counterparty
Three Compound Classes (Term Sheets)	Up to $200 million	2.5% up to 10%	Undisclosed Biotechnology Company
EB-002 Out-license	Up to $62 million	Tiered single digit	MycoMedica Life Sciences
Joint Disease (Pharmaceutical)	$61 million	Not specified (Tiered royalty applies to non-pharma)	Restoration Biologics
Joint Disease (Non-Pharmaceutical)	$21 million	0.25% up to 7%	Restoration Biologics

The company's focus remains on advancing EB-003, but these deals show the channel is active; for instance, the Restoration Biologics licenses grant full control to the licensee for all human and animal applications of the conjugate compounds. Also, Enveric Biosciences continues to benefit from ongoing dialogue and growing interest from established pharmaceutical companies with a strategic focus in neuropsychiatry.

Regulatory Filings (IND application) to the U.S. FDA for clinical access

The most critical channel for Enveric Biosciences' lead candidate, EB-003, is the U.S. Food and Drug Administration (FDA) regulatory pathway, which directly enables clinical trials and subsequent value creation. This is the gate to first-in-human studies.

The path to clinical access for EB-003 is being streamlined:

• FDA advised Enveric Biosciences to proceed directly to submitting its IND application and study protocol for review for EB-003.
• The company expects to file the Investigational New Drug (IND) application for EB-003 in early 2026.
• The IND submission is viewed as an inflection-point for Enveric.
• The company's intellectual property estate supports this, including 26 issued U.S. patents and 60 pending national and international applications.

Successfully navigating this channel is key, especially after completing critical Chemistry, Manufacturing, and Controls (CMC) milestones, including successful 1-kg batch production to support GLP tox and formulation work.

Scientific Publications and industry conferences (e.g., BIO Convention) for data

Presenting data at scientific venues and industry conferences serves as a channel to validate science, attract partners, and engage with investors. This builds the credibility needed for successful out-licensing and regulatory progress.

Key engagement points in 2025 included:

• Participation in the BIO International Convention held June 16-19, 2025, in Boston, Massachusetts, for one-on-one meetings.
• CEO participation in the Sachs Associates 8th Annual Neuroscience Innovation Forum on January 12, 2025, during "J.P. Morgan Week 2025."
• Announcement of publication of two peer-reviewed articles in ACS Chemical Biology and BioDesign Research.

The data presented supports the EB-003 mechanism; for example, Q3 2025 research showed significantly decreased context-induced freezing behavior one-hour post-dose in a preclinical model of PTSD, with a statistical significance of p < 0.05.

Investor Relations for capital markets access (NASDAQ: ENVB)

Access to capital markets is a vital channel for funding operations, especially for a pre-revenue company like Enveric Biosciences. The company relies on financing tools to bridge the gap until potential licensing revenue or clinical milestones are achieved.

Here are the relevant financial metrics as of late 2025:

Metric	Value (as of Q3 2025/Latest Data)
Cash and Cash Equivalents (as of September 30, 2025)	$3.8 million
Net Proceeds Raised (Nine Months Ended September 30, 2025)	$7.9 million
Net Loss (Q3 ending September 30, 2025)	$3.4 million
Diluted EPS Loss (Q3 ending September 30, 2025)	$10.81 per share
Institutional Ownership	7.74%
Insider Ownership	80.21%
Closing Stock Price (November 25, 2025)	$5.94

The company faced capital markets pressure, receiving a bid-price deficiency delisting determination from Nasdaq on October 22, 2025, which necessitated a 1-for-12 reverse stock split. The high insider ownership of 80.21% suggests strong internal conviction in the company's direction, despite the reliance on external financing.

Enveric Biosciences, Inc. (ENVB) - Canvas Business Model: Customer Segments

You're looking at the core groups Enveric Biosciences, Inc. (ENVB) targets to advance its pipeline and secure its runway. This isn't just about who buys the final drug; it's about who funds the science and who licenses the non-core IP. Here's the quick math on the segments as of late 2025, based on their Q3 reporting.

Large Pharmaceutical Companies seeking novel neuropsychiatric pipeline assets

This segment is primarily interested in Enveric Biosciences, Inc.'s lead candidate, EB-003. They seek assets with differentiated mechanisms that address large, unmet needs in mental health. EB-003 is positioned as a potential first-in-class neuroplastogen, engaging both the 5-HT2A and 5-HT1B receptors, which is a dual mechanism they find compelling for developing novel neuropsychiatric treatments.

The value proposition for these partners centers on de-risked, non-hallucinogenic candidates ready for clinical advancement. For instance, Enveric Biosciences, Inc. announced receiving a written response from the U.S. Food and Drug Administration (FDA) to their pre-IND meeting request for EB-003, suggesting preparations are advanced enough to proceed to IND submission. Furthermore, they successfully produced a 1-kilogram batch of EB-003 as a pharmaceutically compatible salt to support upcoming Investigational New Drug (IND) application activities.

Specialty Biotech Licensees for non-core assets (e.g., cannabinoid-COX-2)

Enveric Biosciences, Inc. explicitly focuses on out-licensing other novel, patented drug candidates from its Psybrary™ platform to third-party licensees advancing non-competitive market strategies. This strategy helps generate non-dilutive capital and validates the broader IP portfolio.

Specific assets targeted by this segment include:

• The EVM401 Series of compounds, which includes mescaline-derived compounds targeting addiction, ADHD, anxiety, depression, and substance use disorders.
• Cannabinoid-COX-2 conjugate compounds, for which Enveric Biosciences, Inc. signed two licensing agreements, potentially targeting joint pathologies like osteoarthritis and rheumatoid arthritis.

Future Patients with difficult-to-treat conditions like PTSD and chronic depression

While not direct customers in the current business model, these patients represent the ultimate market and the core driver for the value of the pipeline assets. Enveric Biosciences, Inc.'s focus is on conditions with limited effective treatments.

The preclinical data supporting the appeal to this segment includes:

• Positive effects in a preclinical model of PTSD, showing significantly decreased context-induced freezing behavior one-hour post-dose (p < 0.05).
• Reducing behavioral despair in chronic depression models.

The convenience factor is key: EB-003 is designed for oral administration, requiring no in-clinic dosing, which is a major benefit over some alternatives. If onboarding takes 14+ days, patient retention risk rises, so this oral convenience is defintely a plus.

Institutional and Retail Investors providing equity capital

This segment provides the necessary equity capital to fund the expensive, multi-year path to clinical trials. Enveric Biosciences, Inc. continues to fund operations through various financing tools.

Here are the key financial metrics relevant to this customer segment as of late 2025:

Financial Metric (as of Sept 30, 2025)	Amount
Cash and Cash Equivalents	$3.8 million
Net Loss for Q3 2025	$3.4 million
Net Proceeds Raised (Nine Months Ended Sept 30, 2025)	$7.9 million
Q3 2025 EPS (Adjusted for Reverse Split)	$-10.81

The company's strategy to advance EB-003 toward an IND submission in 2026 is the central catalyst for this group. For context on recent capital activity, Enveric Biosciences, Inc. announced the closing of a $5 million public offering in Q1 2025.

Finance: draft 13-week cash view by Friday.

Enveric Biosciences, Inc. (ENVB) - Canvas Business Model: Cost Structure

You're looking at the cost side of Enveric Biosciences, Inc. (ENVB) as they push toward their 2026 Investigational New Drug (IND) submission for EB-003. For a pre-revenue biotech like Enveric Biosciences, Inc., the cost structure is almost entirely front-loaded into development.

The most immediate figure you need to anchor on is the bottom line for the third quarter of 2025. Enveric Biosciences, Inc. reported a net loss of $3.4 million for the quarter ended September 30, 2025. This loss widened from the $2.5 million loss reported in the second quarter of 2025 and is up from the $2.1 million net loss in the third quarter of 2024. Honestly, this widening loss reflects the ongoing, necessary spend to hit that critical clinical readiness milestone.

The primary driver of this burn rate is Research and Development (R&D) investment. This spend covers everything from preclinical data generation to the expensive, regulated work required before human trials. The financial results for Q3 2025 explicitly reflected this ongoing R&D investment.

Within R&D, you see significant, lumpy costs associated with IND-enabling studies and Chemistry, Manufacturing, and Controls (CMC) work. These are non-negotiable costs to get a drug candidate ready for the Food and Drug Administration (FDA). Enveric Biosciences, Inc. recently completed key CMC milestones, which means they incurred the associated production costs:

• Identified and produced a pharmaceutically compatible salt form.
• Developed and implemented a scalable, reproducible synthetic process.
• Successfully produced a 1-kilogram batch of EB-003 to support IND enabling activities.

General and Administrative (G&A) overhead for corporate operations is the other component of the operating expense base. While specific G&A figures aren't broken out here, the overall net loss indicates the cost of running the corporate structure alongside the science. The company is relying heavily on external financing, having raised net proceeds of $7.9 million for the nine months ended September 30, 2025, to cover these expenses.

Intellectual Property (IP) creation, maintenance, and defense costs are a material, though perhaps less frequent, cost center. Enveric Biosciences, Inc. is actively defending its core assets, evidenced by hiring Fish and Richardson P.C. to defend U.S. Patent No. 12,138,276. This defense is set against a backdrop where a patent relevant to Bretisilocin was part of AbbVie's $1.2 billion acquisition, showing the potential value at stake in their IP portfolio.

Here's a quick look at the key financial metrics surrounding this cost structure as of late 2025:

Financial Metric	Amount (Q3 2025)	Context/Period
Net Loss	$3.4 million	Quarter ended September 30, 2025
Net Loss	$6.58 million	Nine months ended September 30, 2025
Cash and Cash Equivalents	$3.8 million	As of September 30, 2025
Non-Cash Expenses (Stock-Based Comp, etc.)	Approximately $0.2 million	Included in Q3 2025 Net Loss
Net Proceeds Raised YTD	$7.9 million	For the nine months ended September 30, 2025

The net loss for the quarter included approximately $0.2 million in non-cash expenses related to stock-based compensation and other non-cash charges. The company's cash position of $3.8 million as of September 30, 2025, juxtaposed against the quarterly burn, definitely puts financing strategy front and center.

Enveric Biosciences, Inc. (ENVB) - Canvas Business Model: Revenue Streams

You're looking at the current financial reality for Enveric Biosciences, Inc. (ENVB) as of late 2025. Right now, the revenue streams are entirely focused on funding operations through capital markets and securing future, contingent payments from prior deals. This is typical for a company deep in preclinical development.

Zero Revenue Reported for Q1, Q2, and Q3 2025 (Pre-Revenue Stage)

For the first three quarters of fiscal year 2025, Enveric Biosciences, Inc. reported no revenue from product sales or operations. The business remains firmly in a pre-revenue stage, with net losses reported across the quarters, such as a net loss of $3.4 million for the quarter ending September 30, 2025. The focus is entirely on advancing the lead candidate, EB-003, toward an Investigational New Drug (IND) submission targeted for 2026.

Equity Financing

The primary source of operational funding through the first nine months of 2025 has been capital raises. You need to know the burn rate is being offset by these infusions. The company has raised net proceeds of $7.9 million for the nine months ended September 30, 2025. This figure includes $4.9M in net proceeds raised in the first half of 2025 alone. This capital is essential to fund ongoing research and development (R&D) work.

Here's a quick look at the financing activity supporting operations:

Metric	Amount	Period Ending
Net Proceeds Raised (YTD)	$7.9 million	September 30, 2025
Net Proceeds Raised (H1)	$4.9 million	June 30, 2025
Cash and Cash Equivalents	$3.8 million	September 30, 2025

The company continues to fund its operations through the use of various financing tools. Honestly, this reliance on equity is the near-term financial reality.

Future Milestone Payments from Existing and New Out-Licensing Deals

A significant part of Enveric Biosciences, Inc.'s potential revenue model lies in contingent payments from out-licensing agreements executed on non-core assets. These are not guaranteed revenue but represent substantial upside if partners succeed.

• Potential milestone payments from the February 2025 licensing agreements with Restoration Biologics LLC total up to $82 million across pharmaceutical and non-pharmaceutical applications.
• The pharmaceutical license component alone could yield up to $61 million in milestones.
• The non-pharmaceutical license component could yield up to $21 million.
• Term sheets signed in February 2024 contemplated milestone payments up to $200 million across three classes of compounds, assuming all development and sales criteria are met.

These potential payments are tied to specific achievements, such as IND approval and completion of Phase I through Phase III testing.

Future Royalty Payments on Commercialized Licensed Products

Beyond upfront and milestone payments, Enveric Biosciences, Inc. is structured to receive tiered royalty payments on future net sales of any commercialized licensed products. This is the long-term, passive revenue component of the model.

The expected royalty structures are detailed below:

License Agreement	Royalty Range on Future Sales
Restoration Biologics (Pharmaceutical)	2.5% up to 10%
Restoration Biologics (Non-Pharmaceutical)	0.25% up to 7%
MycoMedica Life Sciences (EB-002)	Tiered single digit royalties
Three Classes of Compounds (Term Sheets)	2.5% up to 10%

The Restoration Biologics pharmaceutical license royalties are tiered based on meeting certain sales criteria. If development proceeds successfully, these royalties represent a crucial, scalable revenue stream down the line.